Clinical research
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
Phase II data showed the triple combination treatment provided 16 months of progression-free survival of patients.
The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Phase III SALAMANDER Trial of Rexgenero’s REX-001 Open and Recruiting
Adocia announces the initiation of a Phase 1b study of ADO09, a ready-to-use, fixed ratio co-formulation of pramlintide, the only FDA-approved analog of amylin, and A21G human insulin analog, a rapid-acting insulin that is known to be the main circulating metabolite of insulin glargine.
Takeda said that patients treated with Ninlaro in the Phase III TOURMALINE-AL1 study failed to see a significant improvement in overall hematologic response.
During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.
Bavarian Nordic A/S announced that the Data and Safety Monitoring Board confirmed a partial response in one of the first chordoma patients recruited and treated with the combination of BN-Brachyury and radiation treatment at the first evaluation timepoint.
InflaRx reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.
Companies from across the globe share updates on their pipelines and growth strategies.
PRESS RELEASES